Vps34 regulates myofibril proteostasis to prevent hypertrophic cardiomyopathy-Reference-Cited by-同舟云学术

Vps34 regulates myofibril proteostasis to prevent hypertrophic cardiomyopathy

Published:2017-01-12 Issue:1 Volume:2 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Kimura Hirotaka,Eguchi Satoshi,Sasaki Junko,Kuba Keiji,Nakanishi Hiroki,Takasuga Shunsuke,Yamazaki Masakazu,Goto Akiteru,Watanabe Hiroyuki,Itoh Hiroshi,Imai Yumiko,Suzuki Akira,Mizushima Noboru,Sasaki Takehiko

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference47 articles.

1. Contributions of risk factors and medical care to cardiovascular mortality trends

2. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy

3. Hypertrophic cardiomyopathy

4. Hypertrophic cardiomyopathy: from genetics to treatment

5. Heterogeneity of Clinical Manifestation of Hypertrophic Cardiomyopathy Caused by Deletion of Lysine 183 in Cardiac Troponin I Gene Insight From Two Autopsy Cases With an Identical Sarcomeric Gene Mutation

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting VPS34 in autophagy: An update on pharmacological small-molecule compounds;European Journal of Medicinal Chemistry;2023-08

2. Preserving mitochondria to treat hypertrophic cardiomyopathy: From rare mitochondrial DNA mutation to heart failure therapy?;Journal of Clinical Investigation;2023-07-17

3. Regulated cell death pathways in cardiomyopathy;Acta Pharmacologica Sinica;2023-03-13

4. Phospholipid signaling: phosphoinositide kinases and phosphatases;Plasma Membrane Shaping;2023

5. Autophagy in striated muscle diseases;Frontiers in Cardiovascular Medicine;2022-10-13